Loading...

Stock Performance

Data Provided by Refinitiv. Minimum 15 minutes delayed.


facebook中文版下载app

July 31, 2023 - Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results July 7, 2023 - Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA) July 2, 2023 - Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

facebook中文版下载app

facebook中文版下载app

Investor Relations:
Argot Partners
Sam Martin / Maghan Meyers
(212) 600-1902
Email: sam@argotpartners.com / maghan@argotpartners.com

Media Relations:
Tracy Vineis
(617) 420-4839
Email: media@apellis.com

facebook中文版下载app

Sign up to receive email alerts whenever Apellis Pharmaceuticals, Inc. posts new information to the site. Just enter your email address and click Submit.

Sign Up
加速网络连接 Email Alerts RSS Feeds Contact IR
安卓有没有shadowrocket  壹点加速器免费版  super加速器官网  在国内手机如何看油管  ssr飞机场vpn推荐  佛跳墙变成极光了  twitter特推官网  雷霆加速器app官方版